TOVX

Business Context and Reporting Period

Company: Sheffield Pharmaceuticals, Inc. (formerly Sheffield Medical Technologies, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1997
Business Stage: Development stage enterprise with no commercial product sales to date.
Core Focus: Development and commercialization of the Premaire(TM) Metered Solution Inhaler (MSI System) for respiratory diseases (asthma, COPD) and out-licensing early-stage biomedical technologies (cancer, HIV/AIDS).

Key Financial Metrics

Note: Revenue consists primarily of sublicense fees and interest income. The company has no operating revenue from product sales.

Material Changes vs. Prior Period

• Increased Losses: Net loss increased by approximately $2.48 million (35%) compared to 1996, driven by a one-time $1.65 million charge for the acquisition of in-process technology (Camelot Pharmacal) and increased general and administrative expenses.
• Liquidity Deterioration: Working capital shifted from a positive $1.43 million in 1996 to a negative $837,564 in 1997. Cash on hand dropped by over $1.5 million due to heavy R&D expenditures and the acquisition of the Premaire(TM) MSI System technology.
• Debt Structure: The company issued $1.75 million in 6% Convertible Subordinated Debentures in late 1997, significantly increasing long-term obligations compared to the prior year.
• Revenue Decline: Total revenue decreased by $116,750, primarily due to lower interest income resulting from the deployment of cash reserves into the MSI System acquisition.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Independent auditors have issued a report stating that the company's recurring losses and net deficit raise substantial doubt about its ability to continue as a going concern. Management states survival through 1998 is dependent on obtaining additional financing.
• Capital Needs: The company estimates it requires approximately $17.5 million in committed and anticipated funding for R&D after December 31, 1997. Current cash ($393,608) is insufficient to meet trade payables ($887,782) and research obligations ($470,768).
• Recent Financing (Post-Period): In April 1998, the company secured $650,000 via an equity investment from Zambon Group SpA and $1.25 million via a Series B Convertible Preferred Stock offering. These funds were used to pay a delayed DM 2.0 million license fee to Siemens AG.
• Strategic Partnerships: The company is actively seeking partners for foreign marketing of respiratory drugs and out-licensing early-stage technologies (e.g., HIV/AIDS, cancer) to reduce development costs.
• Regulatory Risks: No products have received FDA approval. Commercialization is contingent on successful clinical trials and regulatory approvals, which are costly and time-consuming.
• Legal Contingency: The company is a defendant in a lawsuit (Dr. Bonnie S. Dunbar v. Sheffield) alleging breach of contract and fraud regarding stock options. An unfavorable outcome could have a material adverse effect.

Investor Verification Checklist

• Financing Status: Verify the status of the definitive agreement with Zambon Group SpA and the sufficiency of the $1.9 million raised in April 1998 to cover the estimated $17.5 million R&D gap.
• Siemens Payment: Confirm that the DM 2.0 million payment to Siemens AG (due Jan 1998, paid April 1998) has been settled to avoid forfeiture of the Premaire(TM) MSI System rights.
• Stock Dilution: Assess the dilutive impact of outstanding options (approx. 4.78 million shares), warrants, and convertible debentures ($1.55 million principal) relative to the 12.65 million common shares outstanding.
• Legal Exposure: Monitor the progress of the Dunbar litigation and potential settlement costs.
• Listing Status: Verify if the company meets AMEX listing criteria, as it currently has a stockholders' deficit and sustained losses, risking delisting to the over-the-counter market.